---
title: "Opdivo (nivolumab) in metastatic non-small cell lung cancer: Drug interactions questions"
description: "Drug interactions questions on Opdivo (nivolumab) in metastatic non-small cell lung cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: Does Yervoy change Opdivo levels (drug interactions)? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/drug-interactions"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Opdivo (nivolumab) in metastatic non-small cell lung cancer: Drug interactions questions

Manufacturer: Bristol-Myers Squibb Company  
Prescribing information: [Opdivo](https://packageinserts.bms.com/pi/pi_opdivo.pdf)

Questions that apply to every indication of Opdivo are on [Opdivo (nivolumab), all indications](https://www.evicenter.com/medical-information/opdivo).

## Drug interactions

<a id="opdivo-drug-interactions"></a>

### Does Yervoy change Opdivo levels (drug interactions)?

Applies to: First-line metastatic NSCLC in adults with no EGFR or ALK genomic tumor aberrations: OPDIVO with YERVOY (PD-L1 ≥1%) or OPDIVO with YERVOY and 2 cycles of platinum-doublet chemotherapy

> “When OPDIVO 3 mg/kg every 2 weeks was administered in combination with ipilimumab 
> 1 mg/kg every 6 weeks, the CL of nivolumab was unchanged compared to OPDIVO 
> administered alone and the CL of ipilimumab was increased by 30% compared to ipilimumab 
> administered alone.”

Source: [OPDIVO: OPDIVO, page 34, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=34)

> “When OPDIVO 360 mg every 3 weeks was administered in combination with ipilimumab 1 mg/kg 
> every 6 weeks and chemotherapy, the CL of nivolumab was unchanged compared to OPDIVO 
> administered alone and the CL of ipilimumab increased by 22% compared to ipilimumab 
> administered alone.”

Source: [OPDIVO: OPDIVO, page 34, captured 2026-11-13](https://packageinserts.bms.com/pi/pi_opdivo.pdf#page=34)

## Related pages
- [Medical information: Opdivo (nivolumab): Metastatic non-small cell lung cancer](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer)
- [Indication](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/opdivo--metastatic-non-small-cell-lung-cancer/guidelines)
